Tag

Viiv Healthcare

All articles tagged with #viiv healthcare

health1 year ago•2 min saved

"Three Times a Year: The Promise of Ultra-Long-Acting Cabotegravir for HIV Prevention and Treatment"

ViiV Healthcare has developed a new, stronger form of the HIV prevention drug cabotegravir, which could be administered as an injection every four months. The new formulation, called "cabotegravir ultra long-acting" (CAB-ULA), showed promising results in a trial, with fewer side effects and longer-lasting effects compared to the current form of the drug. If further trials are successful, this new long-acting injection could revolutionize HIV prevention and treatment.

via Queerty|

#cabotegravir #health #hiv-prevention

healthcare2 years ago•0 min saved

Cabenuva Outperforms Biktarvy in PhIII Trial with 90% Patient Preference

In a Phase III trial comparing ViiV Healthcare's long-acting injectable Cabenuva with Gilead Sciences' daily pill Biktarvy for HIV treatment, the majority of patients preferred the injection over the pill, citing various physical and emotional benefits. Patients also reported improved adherence to the medication and emotional and psychological benefits. The study found that Cabenuva was "non-inferior" to Biktarvy in terms of efficacy and was preferred by 90% of patients after 12 months of treatment.

via Endpoints News|

#biktarvy #cabenuva #healthcare

healthcare2 years ago•6 min saved

ViiV Healthcare promotes HIV prevention and awareness among Black women with innovative campaigns.

ViiV Healthcare is distributing sex-positive activity books as part of its ongoing 'Risk to Reasons' campaign to help Black women feel empowered to have sex-positive conversations and reframe discussions around HIV prevention and services. Seagen has signed a licensing deal with Gracell Biotechnologies, granting the smaller partner rights to certain patents, but the scope of the deal and content of the Seagen patents remain unclear. Moderna may have to pay a hefty sum to settle complaints from two smaller companies that originally licensed the LNP tech to Moderna. Sanofi has lowered the price of its best-selling insulin product, Lantus, by 78% and set a $35 cap on out-of-pocket costs for Lantus for all patients with commercial insurance. Pfizer and Astellas are gunning to add a fourth indication to their cancer drug Xtandi with Phase III trial results released. Eli Lilly’s alopecia areata drug, Olumiant, is off to a good start with dermatologists.

via Endpoints News|

#cancer-drug #eli-lilly #healthcare